Type 2 Diabetes
Merck announces trademark for investigational combination therapy for type 2 diabetes
Published in Obesity and Diabetes Week, January 1st, 2007
Janumet is designed to provide an additional treatment option for patients who need more than one oral agent to help control their blood sugar and is currently under standard review by the U.S. Food and Drug Administration (FDA). Merck expects FDA action on the new drug application (NDA) by the end of March 2007. The company is also moving forward as planned with regulatory filings in countries outside the United States.
Data supporting Janumet previously reported at the 66th...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Obesity Research
Mindless eating leads us to eat 28-45% more calories when foods are low-fat - Pediatric Obesity
Obesity is cited as the number one kids' health issue - Obesity and Diabetes
New findings from Hospital for Sick Children in the area of obesity and diabetes described - Obesity and Diabetes
New obesity and diabetes research from State University of New York outlined - Obesity and Diabetes
New obesity and diabetes study findings have been published by scientists at Steno Diabetes Center - Obesity and Diabetes
Researchers from Erciyes University provide details of new studies and findings in the area of obesity and diabetes in adolescents - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
